Genflow Biosciences PLC Announces Total Voting Rights
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) announced its total issued share capital and voting rights as at 31 October 2025. The company reported 493,547,942 Ordinary Shares outstanding, with none held in treasury, making the total number of voting rights 493,547,942.
Shareholders may use this figure as the denominator to determine whether they must notify a change in their holding under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) ha annunciato la quota azionaria emessa totale e i diritti di voto al 31 ottobre 2025. L'azienda ha riportato 493.547.942 azioni ordinarie in circolazione, nessuna in tesoreria, rendendo il numero totale dei diritti di voto 493.547.942.
Gli azionisti possono utilizzare questa cifra come denominatore per determinare se devono notificare una variazione della loro partecipazione ai sensi delle Regole della Disclosure Guidance and Transparency Rules della Financial Conduct Authority.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) anunció su capital social emitido total y derechos de voto a 31 de octubre de 2025. La empresa informó 493,547,942 Acciones Ordinarias en circulación, ninguna en tesorería, haciendo un total de derechos de voto de 493,547,942.
Los accionistas pueden usar esta cifra como denominador para determinar si deben notificar un cambio en su participación conforme a las reglas de Disclosure Guidance and Transparency Rules de la Financial Conduct Authority.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF)은 2025년 10월 31일 기준 발행된 총 주식 자본 및 의결권을 발표했습니다. 회사는 493,547,942 주의 보통주가 유통 중이며, 어떤 것도 보유금고에 보관되지 않아 의결권의 총수는 493,547,942입니다.
주주들은 이 수치를 사용하여 자신들의 보유 지분 변경을 금융감독당국의 Disclosure Guidance and Transparency Rules에 따라 통지해야 하는지 여부를 판단하는 분모로 사용할 수 있습니다.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) a annoncé son capital social émis total et les droits de vote au 31 octobre 2025. La société a indiqué 493 547 942 actions ordinaires en circulation, aucune n'étant détenue en trésorerie, portant le nombre total de droits de vote à 493 547 942.
Les actionnaires peuvent utiliser ce chiffre comme dénominateur pour déterminer s'ils doivent notifier une modification de leur participation en vertu des règles Disclosure Guidance and Transparency Rules de la Financial Conduct Authority.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) gab seine aktuell ausgegebenen Aktien und Stimmrechte zum Stand vom 31. Oktober 2025 bekannt. Das Unternehmen meldete 493.547.942 Stammaktien im Umlauf, keine in Treasury, wodurch die Gesamtzahl der Stimmrechte 493.547.942 beträgt.
Aktionäre können diese Zahl als Nenner verwenden, um festzustellen, ob sie eine Änderung ihrer Beteiligung gemäß den Disclosure Guidance and Transparency Rules der Financial Conduct Authority melden müssen.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) أعلنت عن إجمالي رأس المال المصرَّح به وحقوق التصويت حتى 31 أكتوبر 2025. أشارت الشركة إلى 493,547,942 سهماً عاديّاً قائماً، ولا وجود لأي أسهم في الخزينة، ما يجعل إجمالي حقوق التصويت 493,547,942.
يمكن للمساهمين استخدام هذا الرقم كمقام لتحديد ما إذا كان عليهم إشعار تغيّر في ملكيتهم بموجب قواعد Disclosure Guidance and Transparency Rules الخاصة بهيئة الرقابة المالية.
- None.
- None.
LONDON, UK / ACCESS Newswire / October 31, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases, announces that the total issued share capital of the Company as at 31 October 2025 consists of 493,547,942 Ordinary Shares none of which are held in treasury. Therefore, the total number of voting rights in the Company is 493,547,942.
The figure of 493,547,942 Ordinary Shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their investment in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Contacts
Genflow Biosciences | Harbor Access |
Dr Eric Leire, CEO | Jonathan Paterson, Investor Relations |
+32-477-495-881 | +1 475 477 9401 |
About Genflow Biosciences
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF)(OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there are no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and X.
-Ends-
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Genflow Biosciences PLC
View the original press release on ACCESS Newswire
FAQ
What is the total number of voting rights for Genflow Biosciences (GENFF) as of 31 October 2025?
How many Ordinary Shares does Genflow Biosciences (GENFF) have outstanding on 31 October 2025?
How should shareholders use the 493,547,942 figure for GENFF?
Does the GENFF voting rights notice affect daily trading or share valuation?
Where can investors find contact details for Genflow Biosciences regarding the voting rights update?
Which regulatory rules reference the voting rights denominator for GENFF disclosures?
